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Abstract
Background. Hepatocellular carcinoma (HCC) has seen a dramatic rise in the USA over the last 30 years. Unresectable
disease is present in 8090% of patients, for which radiofrequency ablation (RFA) is an option. The aim of this study is to
report the long-term survival after laparoscopic RFA. Methods. This is a prospective analysis of 104 patients who underwent
122 ablations for unresectable HCC from April 1997 to December 2006 at a tertiary care center. Overall survival (OS) and
disease-free survival (DFS) were calculated using KaplanMeier curves, excluding 11 patients who subsequently underwent
liver transplantation. Patients were analyzed using Child-Pugh classification, Barcelona Clinic Liver Cancer (BCLC)
staging and various clinical parameters. Results. Median (range) data: age 63 years (4181), lesion size 3.5 cm (110),
number of lesions 1 (15), AFP 26.5 ng/ml (3.743588.5) and time from diagnosis to RFA 2 months (mos) (142). The
median KaplanMeier survival for all patients was 26 mos (OS) while DFS was 14 mos. Univariate analysis demonstrated
improved OS for the absence vs. presence of ascites (31 vs. 15 mos, p0.003), Bilirubin B2 mg/dl vs. ]2 mg/dl (27 vs. 19
mos, p0.01), AFP B400 vs. ]400 (29 vs. 13 mos, pB0.0001) and Child-Pugh Grade (A28, B15, C5 mos, p
0.01). Significant factors for improved DFS: absence vs. presence of ascites (16 vs. 5 mos, p0.02), Bilirubin B2 vs. ]2
(14 vs. 5 mos, p0.0278), AFP B400 vs. ]400 (15 vs. 4 mos, p0.0025), Child-Pugh Grade (A16, B10, C3 mos,
p0.03). Patient age, largest tumor size, number of lesions, INR and albumin did not reach clinical significance. Three and
five-year actual survival rates are 21 and 8.3%, respectively. Conclusions. Our study suggests that RFA may have a positive
impact on survival for unresectable HCC. It also determines which patients fare best after RFA, by determining predictive
factors that improve their survival.
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Introduction
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide and is among the
three most common causes of cancer death [14].
Although traditionally HCC was more prevalent in
eastern societies, it has witnessed an expontenial
growth in the USA. The most common etiology
remains viral hepatitis B or C and alcoholic liver
disease [5]. Current estimates of the prevalence of
hepatitis C virus (HCV) in the USA are 2.7 million,
with approximately 6000 new cases of HCC diag-
nosed per year [6]. Proven treatment modalities with
good long-term survival and low recurrence rates are
liver transplantation and surgical resection. However,
only a small percentage of patients are candidates for
these therapies (1025%) [7,8].
Management of patients with HCC is complex and
is a therapeutic challenge for the transplant team,
medical oncologists, and surgeons. Although liver
transplant and surgical resection remain the gold
standard, very few patients are amenable to this
approach. More than 75% of patients have extensive
disease or severe medical comorbidities, such as late
stage cirrhosis, that exclude them from surgical
transplantation or resection. Traditionally, this subset
of patients is offered locopalliative vs. systemic
chemotherapy or ablative therapies.
Radiofrequency ablation (RFA) is gaining increased
acceptance for the local control of both primary
and metastatic liver tumors. The overall morbidity
and mortality associated with laparoscopic RFA for
HCC remains exceedingly low. We previously re-
ported on the short-term results of laparoscopic
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RFA for unresectable HCC [6]. The aim of this study
is to report our long-term outcomes of RFA for
unresectable HCC, as well as to determine factors
that may predict survival.
Patients and methods
This is a prospective study of patients undergoing
RFA for unresectable HCC. Patients were accrued at
the University of CaliforniaSan Francisco and the
Cleveland Clinic, between April 1997 and October
2006. This study was approved by the institutional
review board, and informed consent was obtained
from all patients before enrollment.
A total of 701 RFAs were performed during this
period. Of these 701 ablations, 122 (17.4%) were
for unresectable HCC. This study is comprised of
104 consecutive patients who underwent 122 abla-
tions. Employing a multidisciplinary approach, pa-
tients were evaluated by medical oncology, hepato-
biliary and transplant surgery, radiology, and the RFA
team. Patients that were ultimately referred for RFA
were not candidates for transplantation and deemed
unresectable due to the extent or location of disease or
coexistent comorbidities, such as cirrhosis, that limited
their ability to undergo an extensive resection. Eleven
patients post ablation were deemed candidates for liver
transplantation and underwent transplantation. As
such these 11 patients were excluded from long-term
survival analysis.
Although patients with up to 10 lesions with a
maximum diameter of 10 cm, as well as those with
limited or no extrahepatic diseases were treated in the
beginning of this study, subsequently we developed
the following inclusion criteria: tumor size B7 cm,
number of lesion B7, less than 20% of liver volume
involved with tumor, absence of biliary dilatation and
no or limited extrahepatic disease. Pre- and post-
operative data were collected for analyses. Preopera-
tive CT scans and bloodwork (complete blood count,
liver function tests, basic chemistry, PT/PTT/INR
and AFP) were performed within 1 week of the
ablations. RFA was performed laparoscopically under
ultrasound guidance. Technical considerations have
previously been published by Siperstein et al. and will
not be reiterated within this paper [25]. Patients were
typically monitored overnight and discharged home
the next day after surgery. Tri-phasic liver CT scans
and labs were repeated at 1 week and every 3 months
thereafter in follow-up.
Data was analyzed using JMP statistical software
5.1.2. To identify prognostic factors, the following
variables were analyzed: age, sex, stage of initial
presentation, number of liver lesions, size of dominant
lesion, presence and location of extrahepatic disease,
initial vs. redo ablation, degree of ascites, encephalo-
pathy, hepatitis, cirrhosis, AFP, bilirubin, Barcelona-
Clinic Liver Cancer Group Stage (BCLC), and
Child-Pugh Classification. Analyses were performed
with the data as continuous variables and divided into
defined categories (ordinal data) as supported by
current literature standards. Univariate KaplanMeier
analyses were performed, and if p50.15, these factors
were analyzed using multivariate Cox proportional
hazards model. Actual and actuarial survival analyses
were also performed using KaplanMeier for overall
survival (OS) and disease-free survival (DFS).
Results
One hundred and four patients underwent 122 RFA
sessions between April 1997 and December 2006 for
unresectable HCC. The mean age was 6291.0
(mean9standard error of the mean with a 95%
confidence interval), (range4181). Patients pre-
sented with an average of 1.690.1 lesions (15)
measuring 3.890.15 cm (110 cm).
The median time frame from diagnosis of HCC to
RFA was 5.9 months (142). The underlying etiology
of hepatitis was as follows: 53% of the patients were
infected with HCV, 12% with hepatitis B virus
(HBV), 22% alcoholic-induced hepatitis, 11% idio-
pathic hepatitis, 2% other causes (which include
autoimmune hepatitis, hemochromatosis, etc).
Patients were followed from enrollment in the study
until December 2006. The following endpoints were
noted: progression of ablated disease, evidence of new
hepatic or extrahepatic disease, and death. The
median follow-up was 23 months ranging from 1 to
83 months, calculated from time of ablation to death
or analysis of the data in December 2006. Actual and
actuarial analyses were compared. Three and five-year
actual survival rates are 21% and 8.3% respectively.
KaplanMeier analyses demonstrate a median survi-
val of 26 months post RFA with an overall median
DFS of 14 months (Figure 1). When extrapolating
recurrence data, the median time to recurrence of a
previously ablated lesion was 10.5 months, while
median time to evidence of new liver lesions was
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Figure 1. KaplanMeier analyses demonstrate a median survival of
26 months post RFA, for patients that were not candidates for
transplantation and deemed unresectable. The overall disease-free
survival was 14 months.
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11 months (pns). Survival data was further ana-
lyzed according to preoperative BCLC staging: A1
(median survival data unreached), A2 (31 months),
A3 (26 months), A4 (23 months), B (25 months),
C (). Disease-free data was also further analyzed by
BCLC staging: A1 (24 months), A2 (31 months), A3
(11 months), A4 (9 months), B (11 months), C (),
p0.43 (Table I).
Preoperative data deemed to be predictive of
prognosis were evaluated. Median OS was 26, 26,
and 25 months for lesions B3, 35, and 5 cm,
respectively, p0.93. DFS based on lesion size was
12, 16, and 14 months respectively, p0.71 (Table I).
There was no difference in OS or DFS between
patients withBor ]3 lesions; OS 26 vs. 27 months
(pns) and DFS 17 vs. 11 months (pns). Child-
Pugh Grade A patients had the best OS of 28 months
with a DFS of 16 months, while Grade C patients had
the worst OS of 5 months and DFS of 3 months,
p0.01 and p0.03, respectively (Figures 2 and 3).
Patients with AFP levels B400 fared significantly
better than those with levels ]400, OS 29 months vs.
13 months (p0.002) and DFS 15 months vs.
4 months (p0.0001) (Figures 4 and 5). The
presence of ascites also had a significantly negative
impact on OS 15 months vs. 31 months (p0.003),
and DFS 5 months vs. 16 months (p0.02) (Figures
6 and 7). Patients with bilirubin levels B2 had
significantly improved OS of 27 months vs. 19 months
(p0.01) and DFS 14 months vs. 5 months (p
0.02) (Figures 8 and 9).
When recurrence data was analyzed based on site of
first recurrence, it was seen that the time to recurrence
of new liver disease was 14.6 months, progression of
ablated disease 14 months, and overall DFS 14 months
(Table I and Figure 1).
The exact cause of death was available for 47
patients. Of the patients 38.3% died of liver failure,
25.5% of extrahepatic progression of disease, and
38.3% of other unrelated causes.
Discussion
Although current literature suggests a survival benefit
of RFA for selected cases of HCC, long-term data
remains scant [912]. The present study examines
Table I. Preoperative laboratory data and Barcelona-Clinic Liver
Cancer Staging was analyzed to determine survival data and
disease-free survival data.
Overall
survival p-Value
Disease-free
survival p-Value
Total cohort 26 14
BCLC A1 a a
BCLC A2 31 31
BCLC A3 26 ns 11 ns
BCLC A4 23 9
BCLC B 25 14
BCLC C b b
Size B3 cm 26 12
Size 35 cm 26 ns 16 ns
Size 5 cm 25 14
Number of
Lesions B3
26 ns 17 ns
Number of
Lesions ]3
27 11
Child-Pugh
Grade A
28 16
Child-Pugh
Grade B
15 0.01 10 0.03
Child-Pugh
Grade C
5 3
AFPB400 29 0.002 15 0.0001
AFP]400 13 4
No Ascites 31 0.003 38 0.02
Ascites 15 16
Bilirubin
B2 (mg/dl)
27 0.01 14 0.03
Bilirubin
]2 (mg/dl)
19 5
Note: Child-Pugh Grade, AFP, ascites, and bilirubin levels all
proved to be statistically significant indicators of survival.
aMedian survival was not reached among this cohort.
bNo patients with BCLC Grade C underwent RFA in this study.
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Figure 2. Overall survival was statistically different based on
preoperative Child-Pugh Grade. Grade A patients demonstrated
the best median survival of 28 months; Grade B, 15 months; and
Grade C, 5 months, p0.01.
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Figure 3. Disease-free survival was also noted to be statistically
different among the Child-Pugh grades: Grade A, 16 months;
Grade B, 10 months; Grade C, 3 months, p0.03.
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both long-term overall and DFS of HCC patients post
ablation. Predictors of OS and DFS were also
identified. In this series, patients offered ablation
were not candidates for transplantation and deemed
unresectable.
The natural progression of HCC is short, with a
3-year survival rate of only 12% [13]. The median
survival of all patients with HCC in the SEER
database between 1992 and 1996 was equally poor,
0.6 years [14]. Although transplantation remains the
most effective and potentially curative option, most
patients are not candidates. Of those patients amen-
able to transplantation, limited availability of donor
organs makes liver transplantation difficult and resec-
tion a viable alternative [1519]. Despite significant
improvements in liver resection technique, the prog-
nosis remains poor with 5-year OS rates of 3344%
and 5-year cumulative recurrence rates of 80100%
[15].
When patients are not candidates for transplanta-
tion and not amenable to undergo resection, alter-
natives include local ablation and or local vs. systemic
chemotherapy. The standard regimen of systemic
doxorubicin has been well studied and infers a median
survival of 6 months [20]. The overall median survival
post ablation was 26 months, and the DFS 14
months. A direct comparison of survival rates across
treatment modalities is not possible, as the exclusion
criteria varies. This cohort of patients undergoing
RFA is encouraging.
Until recently, no consensus existed for patients
with unresectable HCC. The North American Hepa-
tobiliary Task Force, consisting of medical oncolo-
gists, radiologists, and surgeons was recently formed
to approach this complex issue with a multidisciplin-
ary approach [20]. Options for this subset of patients
include transarterial embolization vs. transarterial
chemoembolization. A meta-analyses of embolization
studies conferred a significant survival advantage
[26,27]. For those patients that have contraindica-
tions to chemoembolization or progress despite
treatment, may consider arterial administration of
yttrium-90-impregnated glass or resin microspheres
[20]. A well-accepted alternative treatment option for
HCC is percutaneous injection of ethanol. Despite
improved survival, the high rate of recurrence (50% in
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Figure 4. Patients with preoperative AFPB400 had significantly
improved median overall survival compared to those with levels
]400, 29 vs. 13 months, respectively, p0.0001.
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Figure 5. Similar to overall survival, disease-free survival was
significantly improved for patients with AFPB400 preoperatively,
15 vs. 4 months, p0.0025.
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Figure 6. Patients without any preoperative evidence of ascites had
improved median overall survival post RFA compared to those with
ascites: 31 months vs. 15 months, p0.003.
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Figure 7. Disease-free survival was markedly greater for those
without ascites, 16 vs. 5 months, p0.02.
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2 years) has led investigators to examine alternative
treatments [23].
A number of studies have attempted to identify
predictors of survival post ablation. These include
both tumor and patient characteristics. Guglielmi
et al. outlined and directly compared seven different
staging systems for cirrhotic patients with HCC who
underwent RFA. They identified the BCLC staging
system to offer greater validity and prognostic power
[21]. In this series, no statistical difference in survival
was noted when comparing BCLC stages A, B, and
C. Similarly, DFS decreased with a higher stage, but
statistical significance was not achieved. However,
when utilizing the Child-Pugh Grade, patients with
Grade A had significantly better survival and DFS
compared to Grade B and C patients. Several authors
have identified Child-Pugh classification to be a
significant predictor of survival on both univariate
and multivariate analysis [9,14,22]. Our long-term
results are in accordance with our initial results that
we have reported in the literature [6].
Individual criteria were analyzed to identify deter-
minants of OS and DFS. The presence of moderate to
severe ascites, bilirubin ]2 (mg/dl), and AFP]400
were all found to be predictors of poor outcome.
Finding predictive value of these individual factors is
consistent with our findings of Child-Pugh Grade.
Although current literature identifies tumor size and
number to be predictive of survival, this was not
found in this cohort [1,4,9,21]. Similarly, no statis-
tical difference was noted in DFS based on size or
number of lesions. Size and number of tumors plays a
critical role in determining the choice of therapeutic
modalities. Chen et al. in a prospective randomized
trial found no difference in OS or DFS between
resection and ablation for solitary lesions B5 cm [23].
Wakai et al. also identified that larger tumors have
improved survival with surgical resection, while smal-
ler tumors B4 cm have no difference in survival
approached with ablation or resection [24]. This data
emphasizes the efficacy of RFA regardless of size and
number of lesions. Although the largest tumor in this
series measured 10 cm, our exclusion criteria evolved
over the study period with a defined ablation limit of 7
cm. These criteria continue to expand as survival
benefits are noted and the next generation of laparo-
scopic ablation equipment is made available.
Conclusion
Laparoscopic RFA is a promising safe and effective
treatment modality for patients with primary and
metastatic liver malignancies. RFA suggests a survival
benefit for patients that are not candidates or await
liver transplantation, or are deemed unresectable.
Previous to local therapies this select subgroup of
patients suffered poor outcomes. The results of this
study comparing OS and DFS are encouraging.
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